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Available online 28 May 2013Abstract Barth syndrome (BTHS) patients carrying mutations in tafazzin (TAZ1), which is involved in the final maturation of
cardiolipin, present with dilated cardiomyopathy, skeletal myopathy, growth retardation and neutropenia. To study how
mitochondrial function is impaired in BTHS patients, we generated induced pluripotent stem cells (iPSCs) to develop a novel
and relevant human model system for BTHS. BTHS–iPSCs generated from dermal fibroblasts of three patients with different
mutations in TAZ1 expressed pluripotency markers, and were able to differentiate into cells derived from all three germ layers
both in vitro and in vivo. We used these cells to study the impact of tafazzin deficiency on mitochondrial oxidative
phosphorylation. We found an impaired remodeling of cardiolipin, a dramatic decrease in basal oxygen consumption rate and in
the maximal respiratory capacity in BTHS–iPSCs. Simultaneous measurement of extra-cellular acidification rate allowed us a
thorough assessment of the metabolic deficiency in BTHS patients. Blue native gel analyses revealed that decreased respiration
coincided with dramatic structural changes in respiratory chain supercomplexes leading to a massive increase in generation of
reactive oxygen species. Our data demonstrate that BTHS–iPSCs are capable of modeling BTHS by recapitulating the disease
phenotype and thus are important tools for studying the disease mechanism.
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807A iPS cell model of Barth syndromeIntroduction a decrease in respiratory chain activity in fibroblasts fromBarth syndrome (BTHS, MIM# 302060) is a recessive disorder
characterized by dilated cardiomyopathy, attended with
skeletal myopathy, neutropenia, growth retardation and
increased urinary excretion of 3-methylglutaconic acid in
early childhood (Barth et al., 1983; Spencer et al., 2005;
Takeda et al., 2011). The disease-causing gene was mapped
to the TAZ1 locus in the q28 region of the X chromosome
(Xq28) encoding for the mitochondrial protein tafazzin.
Tafazzin is an evolutionary conserved CoA independent
phospholipid acyltransferase, involved in remodeling of
cardiolipin (CL), the hallmark lipid of mitochondria (Neuwald,
1997; Xu et al., 2006). CL is a constituent of the inner (75%) and
outer (25%) membranes where it plays pleiotropic roles in the
maintenance of membrane complexes and cristae morphology
(Xu et al., 2005; Acehan et al., 2007; Gebert et al., 2009). After
its synthesis CL is deacylated tomonolysocardiolipin (MLCL) and
subsequently reacylated by tafazzin. This remodeling process
maintains the normal content and composition of cardiolipin in
mitochondria. Although tafazzin is ubiquitously expressed in all
human tissues, the remodeled molecular species of cardiolipin
are cell-type and tissue specific. Heart and skeletal muscle,
tissues that require high mitochondrial metabolic activity,
contain mainly tetra-linoleoyl-CL ((C18:2)4-CL) in mitochon-
dria whereas a broader species composition is found in other
tissues, especially in the brain (Schlame et al., 2003; Schlame
et al., 2002; Valianpour et al., 2002; Mckenzie et al., 2006;
Houtkooper et al., 2009). It has been suggested that the
different molecular species of cardiolipin observed in differ-
ent cells and tissues are tailored to match the functional
requirements and/or energetic demands of that cell or tissue
(Houtkooper et al., 2009).
Respiratory chain complexes are organized into higher
oligomeric structures called supercomplexes or respirasomes.
In mammalian cells, complex I (NADH:ubiquinone oxidoreduc-
tase) is associated with dimeric complex III (ubiquinol:
cytochrome c oxidoreductase) and multiple copies of complex
IV (cytochrome c oxidoreductase) (Schägger and Pfeiffer,
2001; Schägger and Pfeiffer, 2000; Moreno-Lastres et al.,
2012). The formation of supercomplexes was suggested to
increase efficiency of respiration and prevent the generation
of reactive oxygen species (Acín-Pérez et al., 2008; Vukotic et
al., 2012; Strogolova et al., 2012; Chen et al., 2012). CL
binding has been shown for all individual complexes of the
respiratory chain and available crystal structures reveal CL in
critical positions in complexes III and IV and the ADP–ATP
carrier (Schwall et al., 2012; Shinzawa-Itoh et al., 2007; Lange
et al., 2001; Pebay-Peyroula et al., 2003). CL molecules at the
interface between individual complexes are thought to be
essential for assembly of these complexes into supercomplexes
(Brandner et al., 2005; Zhang et al., 2002; Wenz et al., 2009;
Pfeiffer et al., 2003; Zhang et al., 2005; Bazán et al., 2012).
Previous studies show that cardiomyocytes contain a unique
composition of CL-dependent membrane complexes. A well-
studied example is the respiratory chain complex IV with its
cardiac tissue-specific subunits VIa, VIIa and VIII (Bachman et
al., 1997; Grossman and Lomax, 1997; Arnaudo et al., 1992;
Lomax et al., 1995). Experiments with yeast as a model
organism or lymphoblasts from BTHS patients showed destabi-
lization of respiratory chain supercomplexes in these cells andBTHS patients (Mckenzie et al., 2006; Barth et al., 1996; Sedlák
and Robinson, 1999).
Although mitochondrial respiratory dysfunction and desta-
bilization of supercomplexes have been reported in fibroblasts
or lymphoblasts from BTHS patients, it has remained open how
these individual effects integrate into cellular metabolism,
and how the differentmutations in the tafazzin gene influence
the cardiolipin composition and mitochondrial function in
different cells and tissues.
To address the pathological changes of cardiac function in
a suitable model system, a tafazzin knock down mouse
model has been designed. However, the late onset of the
cardiac phenotype after 8 months in adult mice did not
reflect the early onset of the disease in human and raised
the question of how well a mouse model resembles the
situation in human tissue (Acehan et al., 2011; Soustek et
al., 2011; Phoon et al., 2012). The recent successes in
generation of human induced pluripotent stem cells (iPSCs)
allow us modeling a disease in a culture dish, which is based
on the unique capacity of these cells to continuously
self-renew and to give rise to all cell types in the human
body (Robinton and Daley, 2012). Indeed, there have been a
number of studies reporting on the successful in vitro
modeling of diseases using iPSCs generated from patients
with a full range of genetically inherited as well as sporadic
diseases (Wu and Hochedlinger, 2011).
In this study we therefore aimed to establish a human iPSC
model system from dermal fibroblasts of BTHS patients. We
found an impaired CL remodeling in BTHS–iPSCs, which
recapitulates the disease phenotype. Assessment of mitochon-
drial function revealed a dramatic decrease in mitochondrial
oxygen consumption in BTHS–iPSCs compared to control cells,
which was not compensated by increased glycolysis. We found
that structural changes in the respiratory chain supercomplexes
are causing defects in energetic coupling and an increase
of reactive oxygen species (ROS), thus, providing a possible
explanation for the pathogenesis of the disease.Material and methods
Generation and culture of BTHS–iPSCs
The study was approved by the ethical commission of
Universitätsmedizin Göttingen. Dermal fibroblasts were
obtained from 3 patients diagnosed with BTHS (Table 1)
and 1 healthy donor (Houtkooper et al., 2009). Cells were
grown in Dulbecco's Modified Eagle's Medium (DMEM;
Invitrogen) containing 10% inactivated fetal bovine serum
(FBS, Sigma), 2 mM L-glutamine (Invitrogen), 1× Non-Essential
Amino Acid (NEAA; Invitrogen), and 50 μM β-mercaptoethanol
(Serva). For transduction of dermal fibroblasts into iPSCs, a
standardized protocol was applied as previously described
(Streckfuss-Bomeke et al., 2012). Briefly, fibroblasts were
infected with the lentivirus encoding all four human transcrip-
tion factors OCT4, SOX2, KLF4 and c-MYC using the STEMCCA
system and cultivated on mitomycin C-inactivated mouse
embryonic fibroblasts (MEFs) in human iPSC medium composed
of DMEM/F12 (Invitrogen) containing 20% knockout serum
replacement (Invitrogen), 1× NEAA, 50 μM β-mercaptoethanol
and 10 ng/ml basic fibroblast growth factor (bFGF, Peprotech)
Table 1 Information of patients, and patient-specific iPSC lines.
BTHS
patient
DNA
mutation
Protein Type of
mutation
ID of iPSC
lines
Phenotype a Primers used for mutation detection Reference
TAZ10 590 GNT Gly197Val Missense TAZ10-3
TAZ10-4
Severe f: 5′GAA TTG AAC TGG AGG ATG TC-3′
r: 5′TCC CTG TCT ATG TTC CAC TC-3′
Houtkooper et al.
(2009)
TAZ13 110-1
AGNAC
r.spl.
Ex2del?
Splice site TAZ13-2
TAZ13-3
TAZ13-4
Severe f: 5′TGC TTC TGG ACC AGT GAG T-3′
r: 5′AGC CAC AAA TCC AAG TCT C-3′
Houtkooper et al.
(2009)
TAZ15 170 GNT Arg57Leu Missense TAZ15-1
TAZ15-5
TAZ15-8
Mild f: 5′TGC TTC TGG ACC AGT GAG T-3′
r: 5′AGC CAC AAA TCC AAG TCT C-3′
Newly recruited
a All patients were diagnosed with BTHS on the basis of (ML)CL analysis of fibroblasts.
808 J. Dudek et al.until iPSC colonies could be manually picked. The gener-
ated iPSCs were passaged using collagenase IV (200 U/ml,
Worthington), gently scraped off with a cell scraper and then
propagated on MEFs in human iPSC medium with medium
change every day at 37 °C with 5% CO2. Human embryonic
stem cells (ESCs) HES3 served as a control (Streckfuss-Bomeke
et al., 2012).
Genomic sequencing
The presence of the TAZ1 mutations in the BTHS–iPSCs and
their absence in the control iPSCs was verified by polymerase
chain reaction-based sequencing of genomic DNA isolated from
iPSCs using Maxwell® 16 DNA purification kit (Promega). The
primer sets used for sequencing were given in Table 1.
Pluripotency characterization of iPSCs
The generated iPSCs were characterized for their
pluripotency by alkaline phosphatase staining, and expression
of pluripotency markers OCT4, SOX2, NANOG, LIN28, SSEA-4,
and TRA-1-60 using RT-PCR analysis and immunofluorescence
staining. Primer sequences and antibodies used have been
described previously (Streckfuss-Bomeke et al., 2012). The
DNA methylation analysis of the promoter regions of OCT4
and NANOG was conducted using bisulfite sequencing assays
by Epigenomics (Berlin) as described in Streckfuss-Bomeke
et al. (2012). Spontaneous iPSC differentiation in vitro was
carried out via embryoid body formation as described in
(Streckfuss-Bomeke et al., 2012). The developmental potential
of generated iPSCs in vivo was studied by teratoma formation
after subcutaneous injection of iPSCs (about 2 × 6-cm dishes at
70% confluence for each mouse) into 8-week-old RAG2−/−γc−/−
immunodeficientmice. 6–8 weeks after injection, tumorswere
dissected, embedded in paraffin, sectioned and stained with
hematoxylin and eosin (H&E).
Mass spectrometry analysis of CL and
monolysocardiolipin (MLCL)
Analysis of CL and MLCL was performed as described in
Houtkooper et al. (2009). In brief, lipids were extracted
from homogenized cells by single phase extraction and
cardiolipin (14:0)4 was added for internal standardization.Extracted lipids were analyzed in a high-performance liquid
chromatography–mass spectrometry (HPLC–MS) system.
Determination of respiratory capacity
Oxygen consumption rate (OCR) and extra-cellular acidification
rate (ECAR) of iPSCs were measured with a XF96 Extracellular
Flux Analyzer (Seahorse Bioscience, Billerica, MA, USA). BTHS
and control iPSCs were cultured onto growth factor-reduced
matrigel-coated (matrigelGFR, BD Biosciences) tissue culture
dishes without feeder layer. Briefly, hiPSCs cultured on MEFs
were digested with collagenase IV, scraped off gently with a
cell scraper and cultured onto matrigelGFR-coated plates in
MEF-conditioned medium containing 10 ng/ml bFGF as de-
scribed before (Pakzad et al., 2010). When hiPSCs reached
confluence, a single cell suspension was obtained by the
digestion of the cells with accutase. BTHS and control iPSCs
were seeded to a density of 5 × 103 cells/well into a
matrigelGFR-coated XF 96-well cell culture microplate one day
before measurements and cultured as a monolayer in
MEF-conditioned medium containing 10 ng/ml bFGF. To
increase the cell survival rate of dissociated iPSCs, 10 μM of
Rho-associated kinase (ROCK) inhibitor Y-27632 was used
90 min before digestion with accutase (Pakzad et al., 2010).
Baseline respiration was measured in unbuffered DMEM
without bicarbonates supplemented with 1 mM pyruvate
and 25 mM glucose after calibration at 37 °C in an incubator
without CO2. Periodic measurements of oxygen consumption
and pH were performed and OCR and ECAR were calculated
from the slopes of change in concentration in these parame-
ters over time. Metabolic states were measured after subse-
quent addition of 1.5 μM oligomycin, 1 μM carbonyl cyanide
4-(trifluoromethoxy)phenylhydrazone (FCCP), 1 μM antimycin
A, and 1 μM rotenone.
For analyzing the growth rate, a single cell suspension was
seeded in the meanwhile at a density of 1 × 105 cells/well in
6-well plate. The cell number was calculated using a cell
counting chamber at 24 h after cell seeding. Each sample was
assayed in duplicates in 3 independent experiments.
Membrane potential measurement
Membrane potential measurements were performed in buffer
MP (20 mM KPi, pH 7.2, 0.6 M sorbitol, 0.1% (w/v) bovine
serum albumin, 10 mMMgCl2, 0.5 mMEDTA, 20 mM succinate,
809A iPS cell model of Barth syndromeand 4 mM malate). The membrane potential (Δψ) sensitive
dye DiSC3(5) (3,3-dipropylthiadicarbocyanine iodide, Mo-
lecular Probes) was added to a final concentration of 1 μM.
100 μg/ml of isolated mitochondria was added and the
specific fluorescence quenching was recorded using a spec-
trometer (F-7000, Hitachi) at an excitation wavelength of
622 nm, and an emission wavelength of 670 nm until a stable
baseline was reached. To inhibit the respiratory chain 9 mM
KCN was added and the dissipated membrane potential was
recorded (Sims et al., 1974).
Blue native PAGE
Mitochondrial membranes were solubilized in 1% digitonin,
20 mM Tris–HCl, pH 7.4, 0.1 mM EDTA, 50 mM NaCl, 10% (w/v)
glycerol, 1 mM PMSF for 30 min at 4 °C. After a clarifying spin
for 15 min at 20,000 ×g and 4 °C, 10× loading dye (100 mM
Bis-Tris pH 7.0, 5% Coomassie brilliant blue G-250, 500 mM
ε-amino n-caproic acid) was added to the supernatant and the
sample was separated on a 3–8% polyacrylamide gradient gel as
described (Dekker et al., 1996).
Miscellaneous
Isolation of mitochondria from BTHS and control iPSCs was
performed as described in (Lazarou et al., 2009). In brief,
cells were homogenized in THE buffer (10 mM HEPES pH 7.4,
300 mM Trehalose, 10 mM KCl, 1 mM EDTA, 1 mM EGTA, and
0.5 mM PMSF) by mechanical disruption. After a clarifying
spin at 400 ×g for 10 min at 4 °Cmitochondria were harvested
from the supernatant by centrifugation at 11,000 ×g for 5 min
at 4 °C. ROS generation of isolated mitochondria was
monitored using H2DFFDA (Invitrogen). Changes of fluores-
cence of 10 μMH2DDFDA in 250 μl assay buffer (20 mMTris–HCl
pH 7.4, 150 mM NaCl, and 1% Triton X-100) was recorded at an
excitation wavelength of 498 nm and an emission wavelength
of 525 nm using a fluorescence spectrophotometer (Hitachi
F-7000) for 10 min. For analysis of mitochondrial protein
content 100,000 cells were lysed in buffer L (50 mM Tris
pH 7.4, 140 mM NaCl, 1 mM MgCl2, 1% NP40, and 2 mM PMSF)
by sonication. Cleared supernatants were normalized for
protein content and subjected to SDS gel electrophoresis
using standard techniques. Proteins were bound to
polyvinylidene fluoride (PVDF) membranes by Western-
blotting and probed using primary antibodies raised in rabbit
and secondary antibodies coupled to horseradish peroxi-
dase. Signals were detected using the ECL detection system
(GE-Healthcare) and X-ray films.
Results
Generation and characterization of BTHS–iPSCs
Dermal fibroblasts were obtained from three male BTHS
patients (TAZ10, TAZ13, and TAZ15) with different muta-
tion sites in the TAZ1 gene (590 GNT, 110-1 AGNAC, 170
GNT) (Houtkooper et al., 2009), and transduced with the
STEMCCA lentiviral vector that contains SOX2, KLF4,OCT4 and
c-MYC, using the standardized protocol reported previously
(Streckfuss-Bomeke et al., 2012). After 4 weeks of infection, anumber of colonies with typical human ESC-like morphology
were manually picked and expanded. At least three indepen-
dent iPSC lines were generated and characterized from each
patient (Table 1). Similarly, control iPSC lines were gener-
ated from one healthy individual (C113), which contains
none of the mutations. All generated BTHS and control iPSCs
showed typical human ESC morphology (Fig. 1A, Supplemen-
tary Figs. S1A–C). Each of iPSC lines has been maintained for
more than 20 passages without any obvious phenotypic
changes.
All generated BTHS and control iPSCs showed alkaline
phosphatase activity (Fig. 1B, Supplementary Figs. S1D–F) and
were positive for human ESC markers NANOG, SOX2, OCT4,
LIN28, SSEA-4 and TRA-1-60 demonstrated by immunofluores-
cence staining (Figs. 1C–H, Supplementary Figs. S1D–F).
Genomic sequencing confirmed that the generated BTHS–iPSC
lines retained the specific mutation sites as in their parental
fibroblasts (Fig. 1I). All mutations are hemizygous because the
TAZ1 gene is located on the X-chromosome and BTHS–iPSCs
are generated from the male patients. In addition, all
generated BTHS and control iPSCs revealed endogenous
expression of several pluripotency marker genes such as
OCT4, SOX2, LIN28 and NANOG at a similar level to human
ESCs by RT-PCR (Fig. 1J). We also analyzed the DNA
methylation status of the OCT4 and NANOG promoters in
generated iPSCs. The OCT4 and NANOG promoters were
hypermethylated in the donor dermal fibroblasts and
hypomethylated in the reprogrammed iPSC lines (Fig. 1K)
confirming the reactivation of endogenous expression of
these two pluripotency genes.
Pluripotency of each iPSC line was assessed by both in
vitro and in vivo differentiation potentials. Upon spontaneous
differentiation via embryoid body formation, the generated
iPSCs were able to differentiate into cells derived from all three
embryonic germ layers in vitro, as detected by expression of
marker proteins specific for mesoderm, smooth muscle α-actin
(α-SMA), for endoderm, α-fetoprotein (AFP) and for ectoderm,
β-III tubulin (Figs. 2A–C, Supplementary Fig. S2). When the
generated iPSCs were subcutaneously injected into immuno-
deficient mice, teratoma formation was observed from all
analyzed iPSC lines. The tumors contained abundant differ-
entiation of advanced derivatives of three embryonic germ
layers (Figs. 2D–F). Thus, these analyses confirmed that the
generated BTHS and control iPSCs are pluripotent.Impaired CL remodeling in BTHS–iPSCs
The characteristic abnormalities of CL remodeling in BTHS
patients have been suggested as a diagnostic tool for the
analysis of BTHS patients (Kulik et al., 2008). To confirm the
generated iPSCs as a model for BTHS, we analyzed the CL
and MLCL contents in a selected set of iPSCs by mass
spectrometry (Fig. 3). Compared to control iPSCs C113,
BTHS–iPSCs TAZ10 and TAZ13 displayed the typical defects
in CL remodeling: lower CL levels, accumulation of MLCL,
and a shift of CL and MLCL towards more saturated species.
In C113 iPSCs, MLCL was hardly detectable, whereas in
TAZ10 and TAZ13 iPSCs MLCL levels were markedly elevated.
For both TAZ10 and TAZ13 cells CL levels were reduced when
compared to C113. In addition, there was a shift towards
higher m/z values for both MLCL and CL in TAZ10 and TAZ13
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Figure 1 Characterization of patient-specific iPSCs. A. A representative human ESC-like colony of established TAZ15 iPSC line was
shown. B. The TAZ15 iPSC colony expresses alkaline phosphatase activity. Scale bar = 50 μm. C–E. Immunocytochemical staining of
TAZ15 iPSCs at passage 8 revealed NANOG, SOX2, and OCT4 expression at nuclei. F. LIN28 expression was abundant in the cytoplasm.
G–H. The expression of SSEA-4 and TRA-1-60 was detected in the plasma membrane. Nuclei were stained with DAPI. Scale bar =
50 μm. I. The results of genomic sequence analysis show the existence of the mutation site in the generated iPSCs. J. RT-PCR analyses
show that the iPSCs express pluripotency markers. Untransduced human fibroblasts (HFBs) and MEFs served as a negative control and
human ESCs used as positive control. K. DNA methylation of OCT4 and NANOG promoter regions was examined by bisulfite genomic
sequencing and compared between untransduced fibroblast from 3 patients and generated iPSCs. Color codes from 0% (yellow), over
50% (green) to 100% (blue) methylation.
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Figure 2 Patient-specific iPSCs are pluripotent. A–C. Immunocytochemical staining of embryoid body-mediated differentiated
TAZ15 iPSCs at day 8 + 25 revealed expression of α-fetoprotein (A), α-smooth muscle actin (B) and βIII-tubulin (C). Nuclei were
stained with DAPI. Scale bar = 50 μm. D–F. Upon subcutaneous injection of undifferentiated iPSCs into RAG2−/−γc−/−
immunodeficient mice, teratoma was formed after 6–8 weeks. The teratoma contains derivatives of all three germ layers,
epithelium (endoderm, D), muscle structure (mesoderm, E) and neural tissue (ectoderm, F). Scale bar = 50 μm.
811A iPS cell model of Barth syndromeiPSCs reflecting the higher degree of saturation of the fatty
acid side chains (compare highest peaks of different CL
clusters; i.e. the peak at m/z = 699.5 in C113 is shifted to
m/z = 701.5 in TAZ10 and TAZ13 and the peak at m/z =
712.5 is shifted to m/z = 714.5 etc.).BTHS–iPSCs display decreased respiration not
compensated by increased glycolysis
To address the molecular pathology of the BTHS–iPSC model,
we analyzed mitochondrial respiration in iPSC derived from
control individuals and BTHS patients. In order to submit iPSCs
to flourescense based oxygen consumption measurement,
iPSCs were digested into single cells and cultured as a
monolayer under feeder-layer free conditions one day before
the measurements as described in the Material and methods.
The change in concentration of molecular oxygen over time
(oxygen consumption rate, OCR) under basal conditions was
first measured for three independent iPSC lines derived
from fibroblasts of patient TAZ15 and three control iPSC
lines (Fig. 4A). We calculated an average OCR of all three
BTHS–iPSC lines and found a significant reduction to 62% of
the basal respiration (Fig. 4B). In the same measurement,
we inhibited the F1FO ATP-synthase by using the specific
inhibitor oligomycin. The decrease of respiration in control
and patient lines is a result of the tight coupling between the
respiratory chain and the F1FO ATP-synthase by the membrane
potential. Subsequent depolarization of the membrane po-
tential with FCCP uncouples the respiratory chain from the
ATP-synthase and reveals the maximal respiratory capacity,
which is significantly reduced in BTHS–iPSCs (Fig. 4A). A block
of complexes I and III with rotenone and antimycin A,
respectively, completely inhibits mitochondrial respiration
and therefore reveals non-mitochondrial O2 consumption
of the cell. The maximum respiratory capacity, defined asthe difference of FCCP uncoupled respiration and residual
non-mitochondrial respiration (OCRFCCP − OCRROTENONE), was
reduced in BTHS–iPSCs (TAZ15) to 53% of control iPSCs (C113)
(Fig. 4C). For these assays cells were plated at a concentration
of 5 × 103 cells/well one day prior to the measurement. To
confirm that a difference in the growth rates of BTHS and
control cells did account for differences in respiration, we
determined cell numbers prior to the measurements and did
not observe significant growth differences among iPSC lines
used (Supplementary Fig. 3A). To exclude that the observed
decreased respiration in BTHS–iPSCs was caused by decreased
mitochondrial content instead of a specific defect in the
respiratory chain function, we analyzed the mitochondrial
protein content of a normalized amount of cells by Western
blot. Our data showed that mitochondrial protein levels
were comparable in BTHS and control iPSCs (Supplementary
Fig. 3B).
Glycolysis allows cells to generate ATP by metabolizing
glucose to lactate in the absence of oxidative phosphoryla-
tion. As lactate is excreted from the cell, the change of pH
over time in an unbuffered medium (extracellular acidifica-
tion rate, ECAR)was assessed to determine the glycolytic rate.
We measured ECAR simultaneously while recording OCR for
three TAZ15 iPSC lines in comparison to three control iPSC
lines. The rate of glycolysis immediately increases after the
block of respiration with oligomycin, which was reverted after
uncoupling with FCCP. Surprisingly, glycolysis in BTHS–iPSCs
was not upregulated to compensate for the decreased
respiration. The ratio of OCR/ECAR indicates the relative
contribution of mitochondrial respiration and glycolysis to the
total energy consumption. Fig. 4D shows a comparable OCR/
ECAR ratio in control and patient iPSCs under all conditions
indicating that despite severely reduced respiration in patient
iPSCs, glycolysis is unable to compensate for this defect.
To assess if the observed respiratory deficiency was a
general characteristic of BTHS patients, we analyzed the
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Figure 3 Cardiolipin remodeling is strongly affected in BTHS–iPSCs. Mass spectrometry analysis of cardolipin (CL) and
monolysocardiolipin (MLCL) contents in C113 control (A) and BTHS TAZ10 (B) and TAZ13 (C) iPSCs. Spectrum is presented as mass
to charge ratio (m/z). Cardiolipin (14:0)4 m/z 619.5 served as an internal standard (i.s.).
812 J. Dudek et al.respiration of iPSC lines generated from two other patients,
TAZ10 and TAZ13. We included control iPSCs generated
previously from two other healthy individuals (WT-D2,
WT-K1) (Streckfuss-Bomeke et al., 2012). The basal OCR
of two iPSC lines of TAZ10 and healthy individuals was
measured, and subsequently oligomycin inhibited respira-
tion and maximal respiratory capacity after addition of FCCP
was determined (Fig. 5A). Basal respiration of TAZ10 iPSCs
was strongly affected when compared to control cells
(36% of control, Fig. 5B). Patient iPSCs hardly responded toaddition of oligomycin and uncoupling using FCCP (Fig. 5A).
We simultaneously measured ECAR of TAZ10 iPSCs during the
experiment in order to determine the rate of glycolysis.
OCR/ECAR ratio in TAZ10 iPSCs was slightly reduced indicating
that the mitochondrial contribution to energy conversion in
patient TAZ10 was lower compared to the control individual,
however glycolysis was insufficient to compensate for the
reduced respiration (Fig. 5C). The measurement of basal
respiration, oligomycin inhibited respiration and FCCP
uncoupled respiration of TAZ13 iPSCs is depicted in Fig. 5D.
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Figure 4 Deficient respiration of hiPSCs derived from Barth syndrome patient TAZ15 is not compensated by glycolysis. A. Oxygen
consumption rate (OCR) of three control hiPSC lines and three hiPSC lines derived from Barth syndrome patient TAZ15. After periodic
measurement of the basal respiration the indicated compounds were subsequently added and the OCR rate was determined. B. For
calculation of basal OCR, averages of all three hiPSC lines derived from patient TAZ15 before compound administration was compared
to control (set to 100%). C. The maximal respiratory capacity is calculated from the average respiration of three iPSC lines after FCCP
administration minus the average of non-mitochondrial O2 consumption after Rotenone treatment (control set to 100%).
D. Extracellular acidification rate (ECAR) was measured simultaneously to OCR and plotted as the ratio OCR/ECAR indicating
metabolic shifting of the cells.
813A iPS cell model of Barth syndromeBasal OCR of TAZ13 iPSCs, carrying a splice acceptor mutation,
was even more affected than other patients and reduced to
32% of control cells (Fig. 5E). The FCCP uncoupled maximal
respiration was affected to a similar extent.
The membrane potential across the inner membrane is
essential for almost all transport processes across the innermembrane of mitochondria. We hypothesized that the
respiratory deficiency in BTHS–iPSCs would result in a
decreased proton pumping activity and a measurable reduc-
tion of the membrane potential. We isolated mitochondria
from control, TAZ10 and TAZ15 iPSCs and used these to
measure the membrane potential by fluorescence quenching
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Figure 5 Inefficient respiration in Barth syndrome iPSCs results in a decreased membrane potential. A. Periodic measurement of OCR
rates of two control and two patient (TAZ10) iPSC lines before and after administration of the indicated compounds. B. Quantification of
the average basal respiration of two TAZ10 iPSC lines measured in A compared to control cells (set to 100%). C. Simultaneous
measurement of ECAR allows the determination of OCR/ECAR ratios. D. Determination of OCR in patient TAZ13 iPSCs compared to
control. E. Quantification of the basal respiration of patient TAZ13 iPSCs compared to control (set to 100%). F. Membrane potential of
isolated mitochondria of iPSCs derived from control and Barth syndrome patients TAZ10 and TAZ15 is determined by fluorescence
quenching of the Δψ dependent dye DiSC3(5). Membrane potential specific decrease of fluorescence is determined by intoxication of
complex IV using KCN. One representative reading is shown.
814 J. Dudek et al.utilizing the membrane potential-sensitive dye DiSC3(5). As
expected, while a strong quenching of fluorescence was
observed in control iPSC mitochondria after dye administra-
tion, mitochondria from BTHS–iPSCs showed a strongly
reduced quenching efficiency, demonstrating a decreased
membrane potential (Fig. 5F). Taken together, these data
show that cardiolipin deficiency in the BTHS–iPSC model
system strongly affectsmitochondrial respiration resulting in a
decreased membrane potential.Respiratory chain complexes are reorganized in
BTHS–iPSCs
For efficient energy transfer, respiratory chain complexes are
organized into large oligomers in the inner membrane,
referred to as supercomplexes. In human mitochondria,
supercomplexes are formed by complex I, which builds a
platform for binding of dimeric complex III and several copies
of complex IV (Schägger and Pfeiffer, 2001; Moreno-Lastres et
815A iPS cell model of Barth syndromeal., 2012). The strong deficiency in respiration in BTHS–iPSC
triggered our interest in the structural organization of
respiratory chain complexes in these patient cells. To address
this question and determine if the analysis of respiratory chain
complexes from control and patient iPSCs was feasible, we
isolated mitochondria from iPSCs TAZ10, TAZ13, TAZ15 and
controls for biochemical analyses. As the cultivation of stem
cells required the presence of a limited amount of MEFs, a
mock isolation of a comparable amount of feeder cell was
performed in parallel. Using the mild detergent digitonin,
we solubilized membranes of isolated mitochondria and
separated membrane protein complexes by Blue-native gel
electrophoresis. For Western blot analysis we used specific
antibodies against components of the respiratory chain:
NDUFB8 (complex I), RIESKE (complex III), and COX5A
and COX6A (complex IV). All four antibodies detected
supercomplexes in the high molecular weight range in
control iPSCs (Fig. 6A). However, these supercomplexes were
strongly reduced or absent in TAZ13 iPSCs. In contrast,
amounts of smaller complexes were increased in TAZ13 iPSCs
compared to control cells. This was especially noticeable
for the heterooligomeric complexes III2–IV, the dimeric
complex III2 and monomeric complex IV. A slightly faster
migration behavior of these complexes in TAZ13 iPSCs either
indicates a different solubilization due to the lack of
cardiolipin or a loss of single components during the
preparation of the samples. A significant detection in
mock isolated MEF mitochondria was only observed, when
highly overexposed, confirming the specificity of the signal
for hiPSC mitochondria (Fig. 6A).
To understand if structural rearrangements were com-
mon to BTHS patients we analyzed mitochondria isolated
from TAZ10 and TAZ15 iPSCs by BN-PAGE (Fig. 6B). Similar
to what was observed for TAZ13 iPSCs, supercomplexes
were strongly reduced or absent in iPSCs of both patients.
TAZ15 iPSCs showed an increase of the complexes III2–IV
and complex III2, similar to TAZ13. However, in TAZ10
iPSCs, the smaller complexes III2–IV and III2 were present in
reduced amounts, indicating a reduced stability of both
complexes. In order to assess protein stability of patient
TAZ10 and TAZ15 iPSCs we analyzed steady state levels of
isolated mitochondria by SDS gel electrophoresis and
subsequent Western-blotting. Mitochondrial proteins were
detected in comparable amounts in all samples (Fig. 6C).
Only a slight decrease of COX5A in both patients' iPSCs and
COX6A in TAZ10 compared to control cells became
apparent. Thus, we conclude that a lack of cardiolipin in
the BTHS–iPSC model respirasome formation is significantly
affected.
Structural reorganization of the respiratory chain is often
associated with less efficient energy coupling and the
generation of reactive oxygen species (ROS). We therefore
asked if due to respirasome reorganization and potential
malfunction in electron transfer ROS productionwas increased
in patient iPSCs. Therefore, we measured ROS in isolated
mitochondria from control and TAZ13 iPSCs using the
fluorescence-based sensor H2DFFDA. Interestingly, mitochon-
dria from Barth syndrome patient TAZ13 showed a significant
increase in ROS generation compared to control cells (Fig. 6D).
Accordingly, dissociation of respirasomes in BTHS patient
iPSCs coincided with an increase in the production of reactive
oxygen species.Discussion
We have developed the first human iPSC-based model for
BTHS, bearing mutations in TAZ1, and demonstrated its
suitability to recapitulate mitochondrial dysfunction of the
disease phenotype. So far, insight into the pathogenesis
of BTHS has been gained primarily from patient derived
fibroblasts and lymphoblasts and a mouse tafazzin knock
down model. BTHS patient fibroblasts and lymphoblasts have
defined the characteristic abnormalities in CL remodeling
and have helped to understand the role of cardiolipin in
shaping mitochondrial morphology and maintaining the
integrity of the respiratory chain (Xu et al., 2005; Acehan
et al., 2007; Mckenzie et al., 2006; Barth et al., 1996).
Recently, the systemic knock down of tafazzin in a mouse
model was described. However, the late onset of clinical
symptoms triggers questions how well the mouse model
recapitulates the situation in human tissue (Acehan et al.,
2011; Soustek et al., 2011), in particular, since recent
research focused on BTHS as a multi-organ disorder, which
has a significant impact on fetal and perinatal male demise,
stillbirth and severe neonatal illness or death (Steward et
al., 2010).
In this study we used dermal fibroblasts derived from three
different patients with distinct mutations in the TAZ1 gene
(Houtkooper et al., 2009) and generated BTHS patient-specific
iPSCs. We fully characterized them in terms of pluripotency
both in vitro and in vivo. Similar to human ESCs, all generated
iPSCs show the self-renewal capacity and are able to
differentiate into derivatives of all three embryonic germ
layers. Importantly, BTHS–iPSCs exhibit the typical defects in
CL remodeling: lower CL levels, accumulation of MLCL, and a
shift of CL and MLCL towards more saturated species. It is
important to note that the CL composition of cultured iPSCs
differs from the CL composition in heart tissue, in which
tetralinoleyl-CL is the predominant form (Houtkooper et al.,
2009). Cultured iPSCs contained the main CL clusters found in
heart, but the linoleic acid content is lower. One likely
explanation is that cultured iPSCs rely predominantly on
glucose as their major source of energy (in contrast to the
heart); therefore, the CL composition in iPSCs does not need
specific adaptation to tetralinoleyl-CL for optimizing high
mitochondrial activity. Similar hypothesis has been suggested
for the CL composition in the brain by Cheng et al. (2008).
Another likely explanation is that the lipid composition in
cultured cells highly depends on the fatty acids available in
the culture medium. A direct correlation of CL fatty acid
composition and fatty acid supplementation in the growth
media has been shown previously for patient fibroblasts
(Valianpour et al., 2003). Further studies should investigate
the CL composition in cultured cardiomyocytes derived from
iPSCs.
In our iPSC model of BTHS, we observed structural
rearrangements of respiratory chain complexes in all iPSC
lines derived from three different patients, which most
dramatically affect the large supercomplexes (respirasomes)
(Figs. 6A and B), consistent with data from Barth patient
derived lymphoblasts (Mckenzie et al., 2006). In these
studies, the I–III2 complexes was the largest respiratory
complexwhich was stable in Barth patients. This form is hardly
visible in Figs. 6A and B, however, extended exposures
confirmed it to be stable in BTHS patient iPSCs (data not
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Figure 6 Rearrangements of mitochondrial respiratory chain supercomplexes in Barth syndrome iPSCs cause inefficient energy
transfer resulting in increased generation of ROS. A and B. Isolated mitochondria from patient and control iPSCs and MEFs as a control
were solubilized in digitonin and analyzed on BN-PAGE. Respiratory chain complexes were visualized by Western blot detection using
indicated antibodies. Arrowheads indicate the large supercomplex forms only present in control mitochondria C. Serial dilutions
of mitochondrial extract were separated in SDS gel electrophoresis and analyzed in Western blot using the indicated antibodies.
D. Measurement of ROS generation over time in isolated mitochondria from TAZ13 hiPSCs using the ROS-specific fluorescence-based
sensor H2DFFDA (arbitrary units).
816 J. Dudek et al.shown). Steady state level protein analysis indicated that
the stability of most constituents of the respiratory chain
complexes is not affected (Fig. 6C). Instead, smaller
assembly forms of respiratory chain complexes, such as
the dimer of complex III2, monomeric complex IV and the
III2–IV heterooligomer become more prominent in BTHS–
iPSCs. Interestingly, these complexes showed a slightly
faster migration behavior in TAZ13 iPSCs. The faster
migration of the monomeric complex IV has been observed
before in lymphoblast of Barth patients (Mckenzie et al.,
2006) and can be either explained by differences in the
solubilization of the complexes due to the absence ofcardiolipin or by the dissociation of single components.
Structural data revealed that components, such as COX6A
form the periphery of the cytochrome c oxidase complex
(Tsukihara et al., 1996) and biochemical data indicate that
dissociation of peripheral subunits occurs with decreasing
CL content (Sedlák and Robinson, 1999).
The formation of respiratory chain supercomplexes is
essential for efficient energy transformation. To evaluate if
the structural reorganization, observed in BTHS patients will
affect mitochondrial respiration, we analyzed the metabo-
lism of BTHS–iPSCs. Patient TAZ10 and TAZ13 iPSCs showed a
strong defect in basal respiration as well as in their maximal
817A iPS cell model of Barth syndromerespiratory capacity, indicative of reduced energy conver-
sion by the respiratory chain complexes. An assessment of
cellular growth rate excluded the possibility that a differ-
ence in cell numbers is responsible for this effect. A
determination of mitochondrial proteins of a normalized
amount of cells also excluded the possibility that impaired
respiration in these cells is a result of decreased mitochon-
drial proliferation. In line with our findings, previous reports
showed that mitochondrial content in BTHS fibroblast
and lymphoblast is rather increased than decreased (Xu et
al., 2005; Barth et al., 1996). We therefore conclude that
the structural remodeling of supercomplexes results in a
decreased mitochondrial respiration, in agreement with
earlier reports on a decreased activity of complexes III and
IV (Xu et al., 2005; Barth et al., 1996). Interestingly, full
uncoupling using FCCP induces respiratory rates comparable
to basal respiration. This is in contrast to what has been
observed for differentiated cells such as fibroblasts. We
speculate that basal respiration of iPSCs is close to maximal
respiration and decreases after initiation of differentiation.
We propose that the mutation in TAZ13 in a splice acceptor
site at the intron 1–exon 2 boundary will result in a
non-functional form of the tafazzin protein, explaining the
severity of this mutant. Patient TAZ15 shows a slightly
milder phenotype in respiratory measurements. Recently, a
yeast mutant resembling the mutation of Barth patient
TAZ15 was described (Whited et al., 2012). The yeast
mutant protein was stable and localized in the IMS within
mitochondria. When the enzymatic transacylase activity was
determined, only prolonged exposure to restrictive condi-
tions decreased enzymatic activity, indicative of a temper-
ature sensitive phenotype of this mutant. We therefore
conclude that differences in the severity of the mutation
might be reflected in the extent of respiratory deficiency.
Clinically, the severity of manifestations of BTHS varies among
patients. Larger sets of BTHS–iPSC lines harboring different
mutations in TAZ1 are therefore valuable to further validate
the patient-specific and mutation site-specific disease pheno-
type and compare pathogenetic mechanisms in diverse forms
of the disease.
In agreement with the idea that supercomplex formation
promotes efficient energy transduction, measurement of the
proton pumping activity in BTHS–iPSCs showed a strong
reduction of the membrane potential in the two patients
analyzed. A reduced membrane potential was also detected
in lymphoblasts from BTHS patients (Xu et al., 2005), but
normal levels of cellular ATP was measured in patient
fibroblasts, which may be due to the increase inmitochondrial
mass (Xu et al., 2005; Barth et al., 1996). Our analyses further
show that the destabilization of supercomplexes results in a
leakage of electrons and thus enhanced generation of ROS. In
support of this observation a yeast model for BTHS, the taz1Δ
strain, displayed accumulation of ROS (Chen et al., 2008).
Complex III is predominantly involved in ROS generation in
mitochondria. Cardiolipin deficiency was shown to cause
structural changes in this complex, affecting the heme centers
which might lower the driving force of electron transfer and
provokes ROS generation (Wenz et al., 2009).
Our data provide clear evidence that the pathogenesis of the
TAZ1 mutations can be modeled in iPSCs derived from patients
with BTHS. Since BTHS is multisystem disorders, characterized
by dilated cardiomyopathy, attended with skeletal myopathyand neutropenia (Barth et al., 1983; Spencer et al., 2005;
Takeda et al., 2011), the iPSC approach is particularly attractive
due to the pluripotent nature of these cells. Future studies will
have to differentiate BTHS–iPSCs into cardiomyocytes, skeletal
muscle cells and other cell types and to assess themitochondrial
and bioenergetic changes in these cell lineages. It will be
important to study whether both, increased ROS generation
and reduced energy supply caused by inefficient respiration,
contribute to the pathogenesis in the heart or other tissues of
BTHS patients. The generation of ROS has been implicated in a
variety of cardiovascular diseases (Dhalla et al., 2000; Ytrehus
et al., 1987). The potentially unlimited number of induced
organ-specific cells will allow us to investigate the molecular
and pathophysiological mechanisms and to establish high-
throughput drug screening.
Conclusion
In summary, we generated iPSCs from patients with BTHS.
As compared with iPSCs derived in a similar fashion from
healthy controls, BTHS–iPSCs exhibited an impaired CL
remodeling, an altered mitochondrial oxygen consumption,
which is not compensated by increased glycolysis, and an
increased generation of ROS, thus demonstrating that iPSC
models recapitulate the phenotypes of the disease.
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